Safety and efficacy of GEMOX plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer

Abstract Aim This study was aimed to evaluate the safety and the efficacy of gemcitabine and oxaliplatin (GEMOX) combined with donafenib plus tislelizumab as the first‐line treatment for patients with unresectable biliary tract cancer (BTC). Methods This is a prospective single‐center exploratory st...

Description complète

Détails bibliographiques

Auteurs principaux:	Longrong Wang, Ning Zhang, Yixiu Wang, Ti Zhang, Weiping Zhu, Anrong Mao, Yiming Zhao, Lu Wang
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2023-06-01
Collection:	Cancer Medicine
Sujets:	biliary tract cancer donafenib first‐line GEMOX tislelizumab
Accès en ligne:	https://doi.org/10.1002/cam4.5924
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!